PREVENT Cancer Preclinical Drug Development Program (PREVENT)

The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. PREVENT is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Read more About PREVENT.

Application Instructions

The PREVENT application submission deadlines are twice per year in November and May.

The next submission deadline is Monday, May 5, 2025.

Instructions for Applying

Please apply using the PREVENT Application System.

Supported Projects

134 Projects from PREVENT Cycles 1 through 26: 

  • 79 Chemoprevention projects
  • 46 Immunoprevention projects
  • 9 Biomarker projects

Read more about supported projects and supported prevention approaches.

Available Resources

  • Efficacy
  • Toxicology
  • Regulatory Support
  • Current Good Manufacturing Practice (CGMP)
  • DCP Repository

View available resources

Program Administration

  • Governance Structure
  • Technology Transfer Considerations

Learn more about program administration